|
Generic Name : Gestodene 75 mcg, ethinylestradiol 30 mcg
Brand Name : GYNERA
Manufacturer : Schering
| Product Name |
Price |
Order link |
| Gynera - 21
Pills x 3 Months |
$36.00 |
 |
(Old Package)
(New Package of Gynera by schering)
Drugs Use.
Oral contraception. The mode of action includes the inhibition of ovulation by suppression of the
mid-cycle surge of luteinising hormone, the inspissation of cervical mucus so as to constitute a
barrier to sperm, and the rendering of the endometrium unreceptive to implantation.
Dosage and method of administration
First treatment cycle: 1 tablet daily for 21 days, starting on the first day of the menstrual cycle.
Contraceptive protection begins immediately.
Contraindications
Combined oral contraceptives (COCs) should not be used in the presence of any of the conditions
listed below. Should any of the conditions appear for the first time during COC use, the product
should be stopped immediately.
• Presence or a history of venous or arterial thrombotic/thromboembolic
events (e.g. deep
venous thrombosis, pulmonary embolism, myocardial infarction) or of
a cerebrovascular
accident.
• Presence or history of prodromi of a thrombosis (e.g. transient
ischaemic attack, angina
pectoris).
• Sickle-cell anemia.
• History of migraine with focal neurological symptoms.
• Diabetes mellitus with vascular involvement.
• The presence of a severe or multiple risk factor(s) for venous or
arterial thrombosis may also
constitute a contraindication (see under "Special Warnings and
Special Precautions for Use".
• Pancreatitis or a history thereof if associated with severe
hypertriglyceridemia.
• Presence or history of severe hepatic disease as long as liver
function values have not
returned to normal.
• History of deterioration of otosclerosis during pregnancy.
• Presence or history of liver tumours (benign or malignant).
-3-
• Known or suspected sex-steroid influenced malignancies (e.g. of
the genital organs or the
breasts).
• Undiagnosed vaginal bleeding.
• Known or suspected pregnancy.
• Hypersensitivity to the active substances or to any of the
excipients.
Pregnancy and lactation
Gynera is not indicated during pregnancy. If pregnancy occurs during treatment with Gynera,
further intake should be stopped. However, extensive epidemiological studies have revealed neither
an increased risk of birth defects in children born to women who used COCs prior tp pregnancy, nor
a tertatogenic effect when COCs were taken inadvertently during early pregnancy.
Lactation may be influenced by COCs as they may reduce the quantity and change the composition
of breat milk. Therefore, the use pf COCs should generally not be recommended until the nursing
mother has completely weaned her child. Small amounts ot the contraceptive steroids and/or their
metyabolites may be excreted with the milk but there is no evidence that this adversely affects infant
health.
Warnings
If any of the conditions/risk factors mentioned below is present, the benefits of COC use should be
weighed against the possible risks for each individual woman and discussed with the woman before
she decides to start using it. In the event of aggravation, exacerbation or first appearance of any of
these conditions or risk factors, the woman should contact her physician. The physician should then
decide on whether COC use should be discontinued.
More Information please view :
Gynera Full Description.
|
